文献速递中枢神经肿瘤放疗头颈部肿瘤放疗

识别头颈部或中枢神经系统恶性肿瘤质子治疗后发生重度听力障碍风险的儿童患者

Identifying paediatric patients at risk of severe hearing impairment after treatment for malignancies of the H&N/CNS with proton therapy.
PubMed 文献 · Radiother Oncol · 2024-10-28

单中心研究纳入2010年2月至2022年2月接受质子治疗的587例≤18岁头颈部或中枢神经系统恶性肿瘤患者,验证Keilty等2021年基于光子放疗的风险预测模型。模型区分度良好,最佳截断值16%时特异度和敏感度均为82%,但校准欠佳,模型高估重度听力损失风险。

要点

  • Keilty光子放疗模型在质子治疗队列中区分度良好,最佳截断值16%时特异度和敏感度均为82%。
  • 模型校准欠佳,高估了本队列临床观察到的重度听力损失风险。
  • 高估可能与模型开发者和本研究的事件评分差异及本研究随访时间短有关。

核心结论

  • Keilty等发表的光子放疗模型在质子治疗背景下得到验证,对区分重度听力障碍高风险与低风险患者显示出高区分能力。
  • 然而本队列观察到的总体风险低于模型预测值。

研究设计与样本

  • 单中心研究,提取2010年2月至2022年2月间接受质子治疗的全部≤18岁头颈部或中枢神经系统恶性肿瘤患者数据。
  • 提取Keilty模型所需输入因素:质子治疗时年龄、质子治疗结束至今时间、耳蜗平均剂量和铂类化疗剂量。
  • 使用R v 4.3.1软件进行验证,分析事件区分度和模型校准。

主要发现

  • 587例患者符合标准。
  • 模型验证显示极好的区分能力,最佳截断值为16%时特异度和敏感度均为82%。
  • 模型校准欠满意,模型高估了本队列临床观察到的重度听力损失风险,可能与模型开发者与本研究的事件评分差异及本研究随访时间短有关。

关键数值与推荐

  • Keilty模型所需输入因素包括质子治疗时年龄、质子治疗结束至今时间、耳蜗平均剂量和铂类化疗剂量。
  • 最佳截断值为16%时,特异度和敏感度均为82%。

局限性

  • 模型校准欠满意,模型高估了本队列临床观察到的重度听力损失风险。
  • 高估可能与模型开发者与本研究的事件评分差异有关。
  • 高估可能与本研究随访时间短有关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: A risk calculation model was presented in 2021 by Keilty et al. for determining the likelihood of severe hearing impairment (HI) for paediatric patients treated with photon radiation therapy. This study aimed to validate their risk-prediction model for our cohort of paediatric patients treated with proton therapy (PT) for malignancies of the head and neck (H&N) or central nervous system (CNS). MATERIALS AND METHODS: This was a single-institution study which extracted data on all patients aged ≤ 18 years treated with PT between Feb 2010 - Feb 2022 for malignancies of the H&N/CNS. The factors required for input into the Keilty model were extracted: age at PT, time since end of PT, mean cochlea dose, and platinum chemotherapy doses. Validation was performed using the statistical software R v 4.3.1, which analysed event discrimination and model calibration. RESULTS: 587 patients met the criteria. Validation of the model demonstrated excellent discriminative ability, with an "optimal" cut-off value of 16% at a specificity and sensitivity of 82%. However, model calibration was less satisfactory, indicating an overestimation of risk of severe hearing loss (HI) by the model as compared to clinically observed events in our cohort, possibly linked to differences in event scoring between the model developers and this study, and short follow-up time in this study. CONCLUSION: The published (photon-based) model of Keilty et al. was validated in a PT context, demonstrating a high discriminative ability to determine patients at high risk versus low risk for severe HI. However the overall observed risk was lower than model predictions.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Gaito S, Hwang E, Thwaites D, et al. Identifying paediatric patients at risk of severe hearing impairment after treatment for malignancies of the H&N/CNS with proton therapy. Radiother Oncol. 2024. PMID: 39490418. doi:10.1016/j.radonc.2024.110597

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。